Journal of Gastroenterology and Hepatology

Volume 39, Issue 11 pp. 2439-2446

Original Article - Hepatology (Clinical)

Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus

Yu-Ping Chang,

Yu-Ping Chang

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Chen-Hua Liu,

Chen-Hua Liu

orcid.org/0000-0003-3622-9707

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

Search for more papers by this author

Chiuan-Bo Huang,

Chiuan-Bo Huang

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Ji-Yuh Lee,

Ji-Yuh Lee

Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

Search for more papers by this author

Chun-Jen Liu,

Chun-Jen Liu

orcid.org/0000-0002-6202-0993

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Search for more papers by this author

Tung-Hung Su,

Tung-Hung Su

orcid.org/0000-0002-6747-7941

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Shang-Chin Huang,

Shang-Chin Huang

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan

Search for more papers by this author

Tai-Chung Tseng,

Tai-Chung Tseng

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Pei-Jer Chen,

Pei-Jer Chen

orcid.org/0000-0001-8316-3785

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Search for more papers by this author

Jia-Horng Kao,

Corresponding Author

Jia-Horng Kao

[email protected]

orcid.org/0000-0002-2442-7952

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Correspondence

Prof Jia-Horng Kao, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei 10002, Taiwan.

Email: [email protected]

Search for more papers by this author

Yu-Ping Chang,

Yu-Ping Chang

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Chen-Hua Liu,

Chen-Hua Liu

orcid.org/0000-0003-3622-9707

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

Search for more papers by this author

Chiuan-Bo Huang,

Chiuan-Bo Huang

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Ji-Yuh Lee,

Ji-Yuh Lee

Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan

Search for more papers by this author

Chun-Jen Liu,

Chun-Jen Liu

orcid.org/0000-0002-6202-0993

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Search for more papers by this author

Tung-Hung Su,

Tung-Hung Su

orcid.org/0000-0002-6747-7941

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Shang-Chin Huang,

Shang-Chin Huang

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan

Search for more papers by this author

Tai-Chung Tseng,

Tai-Chung Tseng

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Search for more papers by this author

Pei-Jer Chen,

Pei-Jer Chen

orcid.org/0000-0001-8316-3785

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Search for more papers by this author

Jia-Horng Kao,

Corresponding Author

Jia-Horng Kao

[email protected]

orcid.org/0000-0002-2442-7952

Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan

Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan

Correspondence

Prof Jia-Horng Kao, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 7 Chung-Shan South Road, Taipei 10002, Taiwan.

Email: [email protected]

Search for more papers by this author

First published: 10 July 2024

https://doi.org/10.1111/jgh.16680

Citations: 1

Yu-Ping Chang and Chen-Hua Liu contribute equally to the work.

Declaration of conflict of interest: Chen-Hua Liu: Advisory board for Sysmex; speaker's bureau for Sysmex. Jia-Horng Kao: Advisory board for Sysmex; speaker's bureau for Sysmex. All the other authors declare no competing interests.

Author contribution: Conceptualization: Yu-Ping Chang, Chen-Hua Liu, and Jia-Horng Kao. Data curation: Chen-Hua Liu. Formal analysis: Yu-Ping Chang and Chen-Hua Liu. Investigation: Yu-Ping Chang, Chen-Hua Liu, Chiuan-Bo Huang, Ji-Yuh Lee, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Pei-Jer Chen, and Jia-Horng Kao. Methodology: Yu-Ping Chang and Chen-Hua Liu. Project administration: Yu-Ping Chang, Chen-Hua Liu, and Jia-Horng Kao. Resources: Yu-Ping Chang, Chen-Hua Liu, Chiuan-Bo Huang, Ji-Yuh Lee, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Pei-Jer Chen, and Jia-Horng Kao. Software: Chen-Hua Liu. Supervision: Jia-Horng Kao. Validation: Yu-Ping Chang and Chen-Hua Liu. Visualization: Yu-Ping Chang and Chen-Hua Liu. Writing—original draft: Yu-Ping Chang, Chen-Hua Liu, and Jia-Horng Kao. Writing—review and editing: Yu-Ping Chang, Chen-Hua Liu, Chiuan-Bo Huang, Ji-Yuh Lee, Chun-Jen Liu, Tung-Hung Su, Shang-Chin Huang, Tai-Chung Tseng, Pei-Jer Chen, and Jia-Horng Kao.

Financial support: The study was supported by the National Taiwan University Hospital (113-S0040).

Share a link

Email
Wechat
Bluesky

Abstract

Background and Aim

Understanding the dynamics of serum Mac-2 binding protein glycosylation isomer (M2BPGi) remains pivotal for hepatitis C virus (HCV) patients' post-sustained virologic response (SVR₁₂) through direct-acting antivirals (DAAs).

Methods

We compared areas under receiver operating characteristic curves (AUROCs) of M2BPGi, FIB-4, and APRI and assess M2BPGi cutoff levels in predicting fibrosis stages of ≥F3 and F4 utilizing transient elastography in 638 patients. Variations in M2BPGi levels from pretreatment to SVR₁₂ and their association with pretreatment alanine transaminase (ALT) levels and fibrosis stage were investigated.

Results

The AUROCs of M2BPGi were comparable to FIB-4 in predicting ≥F3 (0.914 vs 0.902, P = 0.48) and F4 (0.947 vs 0.915, P = 0.05) but were superior to APRI in predicting ≥F3 (0.914 vs 0.851, P = 0.001) and F4 (0.947 vs 0.857, P < 0.001). Using M2BPGi cutoff values of 2.83 and 3.98, fibrosis stages of ≥F3 and F4 were confirmed with a positive likelihood ratio ≥10. The median M2BPGi change was −0.55. Patients with ALT levels ≥5 times ULN or ≥F3 demonstrated more pronounced median decreases in M2BPGi level compared to those with ALT levels 2–5 times ULN and <2 times ULN (−0.97 vs −0.68 and −0.44; P < 0.001) or with < F3 (−1.52 vs −0.44; P < 0.001).

Conclusions

Serum M2BPGi is a reliable marker for advanced hepatic fibrosis. Following viral clearance, there is a notable M2BPGi decrease, with the extent of reduction influenced by ALT levels and fibrosis stage.

Graphical Abstract

▪▪

Open Research

Data availability statement

Data for this study can be made available upon reasonable request to the corresponding author.

Supporting Information

References

1Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol. Hepatol. 2022; 7: 396–415.
10.1016/S2468-1253(21)00472-6
PubMed Web of Science® Google Scholar
2Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345: 41–52.
10.1056/NEJM200107053450107
CAS PubMed Web of Science® Google Scholar
3Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–832.
10.1016/S0140-6736(96)07642-8
CAS PubMed Web of Science® Google Scholar
4Liu CH, Kao JH. Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int. J. Nanomedicine 2014; 9: 2051–2067.
PubMed Web of Science® Google Scholar
5Zeuzem S, Foster GR, Wang S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N. Engl. J. Med. 2018; 378: 354–369.
10.1056/NEJMoa1702417
CAS PubMed Web of Science® Google Scholar
6Feld JJ, Jacobson IM, Hézode C et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N. Engl. J. Med. 2015; 373: 2599–2607.
10.1056/NEJMoa1512610
CAS PubMed Web of Science® Google Scholar
7Liu CH, Chen PY, Chen JJ et al. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan. Hepatol Int. 2021; 15: 338–349.
10.1007/s12072-021-10158-x
PubMed Web of Science® Google Scholar
8Liu CH, Peng CY, Liu CJ et al. Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan. Hepatol Int. 2023; 17: 291–302.
10.1007/s12072-022-10475-9
PubMed Web of Science® Google Scholar
9Carrat F, Fontaine H, Dorival C et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019; 393: 1453–1464.
10.1016/S0140-6736(18)32111-1
CAS PubMed Web of Science® Google Scholar
10Hutchinson SJ, Valerio H, McDonald SA et al. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study. Gut 2020; 69: 2223–2231.
10.1136/gutjnl-2019-320007
PubMed Web of Science® Google Scholar
11Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 517–524.
10.7326/0003-4819-132-7-200004040-00002
CAS PubMed Web of Science® Google Scholar
12EASL recommendations on treatment of hepatitis C: final update of the series(☆). J. Hepatol. 2020; 73: 1170–1218.
10.1016/j.jhep.2020.08.018
PubMed Web of Science® Google Scholar
13Hepatitis C. Guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin. Infect. Dis. 2018; 67: 1477–1492.
10.1093/cid/ciy585
PubMed Web of Science® Google Scholar
14Omata M, Kanda T, Wei L et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016; 10: 702–726.
10.1007/s12072-016-9717-6
PubMed Web of Science® Google Scholar
15Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med. 2001; 344: 495–500.
10.1056/NEJM200102153440706
CAS PubMed Web of Science® Google Scholar
16Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449–1457.
10.1016/j.hep.2003.09.022
PubMed Web of Science® Google Scholar
17Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020; 69: 1343–1352.
10.1136/gutjnl-2018-317593
CAS PubMed Web of Science® Google Scholar
18Shirabe K, Bekki Y, Gantumur D et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J. Gastroenterol. 2018; 53: 819–826.
10.1007/s00535-017-1425-z
CAS PubMed Web of Science® Google Scholar
19Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical utility of Mac-2 binding protein glycosylation isomer in chronic liver diseases. Ann. Lab. Med. 2021; 41: 16–24.
10.3343/alm.2021.41.1.16
CAS PubMed Web of Science® Google Scholar
20Kuno A, Ikehara Y, Tanaka Y et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 2013; 3: 1065.
10.1038/srep01065
CAS PubMed Web of Science® Google Scholar
21Xu H, Kong W, Liu L et al. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. BMC Gastroenterol. 2017; 17: 62.
10.1186/s12876-017-0618-5
PubMed Web of Science® Google Scholar
22Saleh SA, Salama MM, Alhusseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. World J. Gastroenterol. 2020; 26: 2864–2876.
10.3748/wjg.v26.i21.2864
CAS PubMed Web of Science® Google Scholar
23Chuaypen N, Chittmittrapap S, Avihingsanon A et al. Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. Hepatol. Res. 2021; 51: 528–537.
10.1111/hepr.13630
CAS PubMed Web of Science® Google Scholar
24Ueda N, Kawaoka T, Imamura M et al. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. BMC Gastroenterol. 2020; 20: 314.
10.1186/s12876-020-01459-w
CAS PubMed Web of Science® Google Scholar
25Liu CH, Liu CJ, Su TH et al. Serum Mac-2 binding protein glycosylation isomer to predict the severity of hepatic fibrosis in patients with hepatitis C virus infection. Diagnostics (Basel) 2022; 12.
Web of Science® Google Scholar
26Fujita K, Kuroda N, Morishita A et al. Fibrosis staging using direct serum biomarkers is influenced by hepatitis activity grading in hepatitis C virus infection. J. Clin. Med. 2018; 7.
10.3390/jcm7090267
Web of Science® Google Scholar
27Liu CH, Liang CC, Liu CJ et al. Comparison of Abbott RealTime HCV Genotype II with Versant line probe assay 2.0 for hepatitis C virus genotyping. J. Clin. Microbiol. 2015; 53: 1754–1757.
10.1128/JCM.03548-14
CAS PubMed Web of Science® Google Scholar
28Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol. 2008; 48: 835–847.
10.1016/j.jhep.2008.02.008
PubMed Web of Science® Google Scholar
29Prati D, Taioli E, Zanella A et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann. Intern. Med. 2002; 137: 1–10.
10.7326/0003-4819-137-1-200207020-00006
CAS PubMed Web of Science® Google Scholar
30Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317–1325.
10.1002/hep.21178
CAS PubMed Web of Science® Google Scholar
31Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–526.
10.1053/jhep.2003.50346
CAS PubMed Web of Science® Google Scholar
32Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839–843.
10.1148/radiology.148.3.6878708
CAS PubMed Web of Science® Google Scholar
33Puhan MA, Steurer J, Bachmann LM, ter Riet G. A randomized trial of ways to describe test accuracy: the effect on physicians' post-test probability estimates. Ann. Intern. Med. 2005; 143: 184–189.
10.7326/0003-4819-143-3-200508020-00004
PubMed Web of Science® Google Scholar
34Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005; 365: 1500–1505.
10.1111/j.1532-5415.2004.52073.x
PubMed Web of Science® Google Scholar
35Castéra L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343–350.
10.1053/j.gastro.2004.11.018
PubMed Web of Science® Google Scholar
36Liu CH, Hsu SJ, Lin JW et al. Noninvasive diagnosis of hepatic fibrosis in patients with chronic hepatitis C by splenic Doppler impedance index. Clin. Gastroenterol. Hepatol. 2007; 5: 1199–1206.e1.
10.1016/j.cgh.2007.07.017
PubMed Web of Science® Google Scholar
37Yen YH, Kuo FY, Kee KM et al. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS ONE 2018; 13: e0199760.
10.1371/journal.pone.0199760
PubMed Web of Science® Google Scholar
38Catanzaro R, Aleo A, Sciuto M, Zanoli L, Balakrishnan B, Marotta F. FIB-4 and APRI scores for predicting severe liver fibrosis in chronic hepatitis HCV patients: a monocentric retrospective study. Clin Exp Hepatol. 2021; 7: 111–116.
10.5114/ceh.2021.104543
PubMed Web of Science® Google Scholar
39Liu CH, Fang YJ, Liu CJ et al. Splenic arterial pulsatility index to predict hepatic fibrosis in hemodialysis patients with chronic hepatitis C virus infection. J. Clin. Med. 2023; 12.
10.3390/jcm12052020
Web of Science® Google Scholar
40Yasui Y, Abe T, Kurosaki M et al. Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. Hepatol. Res. 2019; 49: 33–41.
10.1111/hepr.13286
CAS PubMed Web of Science® Google Scholar
41Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60: 1563–1570.
10.1002/hep.27305
CAS PubMed Web of Science® Google Scholar
42Tamaki N, Kurosaki M, Kuno A et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol. Res. 2015; 45: E82–E88.
10.1111/hepr.12466
CAS PubMed Web of Science® Google Scholar
43Sasaki R, Yamasaki K, Abiru S et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein values predict the development of hepatocellular carcinoma among patients with chronic hepatitis C after sustained virological response. PLoS ONE 2015; 10: e0129053.
10.1371/journal.pone.0129053
PubMed Web of Science® Google Scholar
44Nagata H, Nakagawa M, Asahina Y et al. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J. Hepatol. 2017; 67: 933–939.
10.1016/j.jhep.2017.05.028
CAS PubMed Web of Science® Google Scholar
45Yasui Y, Kurosaki M, Komiyama Y et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. Hepatol. Res. 2018; 48: 1131–1139.
10.1111/hepr.13233
CAS PubMed Web of Science® Google Scholar
46Osawa L, Tamaki N, Kurosaki M et al. Wisteria floribunda agglutinin-positive Mac-2 binding protein but not α-fetoprotein as a long-term hepatocellular carcinoma predictor. Int. J. Mol. Sci. 2020; 21: 3640.
10.3390/ijms21103640
CAS PubMed Web of Science® Google Scholar
47Asahina Y, Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. JSH guidelines for the management of hepatitis C virus infection, 2019 update; protective effect of antiviral therapy against hepatocarcinogenesis. Hepatol. Res. 2020; 50: 775–790.
10.1111/hepr.13501
PubMed Web of Science® Google Scholar
48Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358–380.
10.1002/hep.29086
PubMed Web of Science® Google Scholar
49Kim NJ, Vutien P, Cleveland E, Cravero A, Ioannou GN. Fibrosis stage-specific incidence of hepatocellular cancer after hepatitis C cure with direct-acting antivirals: a systematic rseview and meta-analysis. Clin. Gastroenterol. Hepatol. 2023; 21: 1723–1738.e5.
10.1016/j.cgh.2022.04.013
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume39, Issue11

November 2024

Pages 2439-2446